News

Pfizer says it will appeal the Aug 1 ruling to Britain’s Supreme Court. Read more at straitstimes.com. Read more at ...
Moderna trimmed its 2025 revenue forecast on Friday after UK deliveries of some COVID vaccines were deferred to next year, ...
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
Circular RNA may be part of the solution. Because circular RNA has no ends to degrade—unlike linear RNA—the molecule is more stable and its half-life is extended.
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Live Updates Live Coverage Updates appear automatically as they are published. Moderna Still Sickly 9:49 am In further ...
Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss ...
A U.K. Court of Appeals ruling confirms the validity of a patent covering modifications of mRNA used in Moderna’s vaccines.
Shares of Moderna fell sharply Friday after the company lowered the top end of its full-year revenue outlook because of a ...
Today, Benzinga 's options scanner spotted 17 uncommon options trades for Moderna. This isn't normal. The overall sentiment of these big-money traders is split between 52% bullish and 35%, bearish.
Despite the overall decline in commercial product revenue, Moderna was also pleasantly surprised by Q2 Spikevax sales, which ...
It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough ...